(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Finding the Universe of Workmanship: Individual Encounters in Imagination- A definitive Burger Confrontation: Which One Rules?
- US bishops officially ban gender-affirming care at Catholic hospitals
- 4 Famous Attractions at Disneyland
- SpaceX shatters its rocket launch record yet again — 165 orbital flights in 2025
- Top 5 Top of the line Books of the Year
- Mississippi Insight for Jan. 11, 2026
- There are thousands of aligned holes in Peru. Archaeologists now think they know who made them
- Vote In favor of Your #1 Method for diminishing Pressure
